Project Grant R43TR005284
Award Date 9/16/25
Completion Date 9/15/26
Dollars Obligated $350K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Mexico, USA
Similar Awards
- This $248,492 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports the development of a "Hydrogen Sulfide Delivery Technology for Organ Preservation Therapy" by Exhalix, LLC, a for-profit company based in Albuquerque, New Mexico. The project aims to address the significant shortage of viable donor kidneys for transplantation by developing a technology...
- This $689,928 Project Grant awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a novel method for delivering localized chelation therapy to remove arterial calcification in patients with peripheral artery disease (PAD). The project will leverage the awardee's University of Nebraska expertise in evaluating over 1,000 human lower extremity arteries and a preclinical large animal model of arterial calcification....
- This National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Project Grant award of $285,444, effective August 15, 2025 through August 14, 2026 (CFDA 93.350), aims to develop recombinant human enzyme panels representing genetic variants of drug-metabolizing enzymes present in the U.S. patient population. The goal is to bridge shortcomings in current in vitro drug metabolism testing, which typically relies on liver microsomes or hepatocytes from...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
- This Project Grant award of $786,188, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene therapy platform to prevent the failure of prosthetic bypass grafts used to treat arterial blockages in the lower extremities. The research, conducted by Beth Israel Deaconess Medical Center, Inc. (BIDMC), focuses on optimizing a biodegradable hydrogel system that can deliver small interfering RNA...
- This federal Project Grant award of $306,867 from the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) supports the project "RAPID CONTROL AND ASSESSMENT OF DISSOLVED GAS SIGNALS ON TISSUE FUNCTION AND DISEASE" at Entox Sciences, Inc. in Seattle, WA. The project aims to develop instrumentation and methods to rapidly control and assess the effects of biologically important gases, including hydrogen sulfide, nitric oxide,...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $280,160 to Palladias LLC, a for-profit company based in Los Alamos, New Mexico. The grant supports the development of inexpensive and reusable sorbents that can effectively remove palladium from the products of palladium-catalyzed cross-coupling reactions, which are widely used in pharmaceutical discovery but not readily...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $1,050,276 Project Grant to Syntr Health Technologies, Inc. on September 25, 2025 under the CFDA 93.350 Federal Grant Program. This funding supports the development and automation of an FDA-cleared CD-microfluidic platform for rapid tissue microsizing. The platform technology can process a variety of tissue types, including cancer tumors and adipose tissue, to enable single-cell analysis and regenerative medical...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...